Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Proton pump inhibitor use and fracture risk - effect modification by histamine H1 receptor blockade. Observational case-control study using National Prescription Data

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Preserved postprandial suppression of bone turnover markers, despite increased fasting levels, in postmenopausal women

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The role of endogenous GIP and GLP-1 in postprandial bone homeostasis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. High serum FSH is not a risk factor for low bone mineral density in infertile men

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Consumption of nutrients and insulin resistance suppress markers of bone turnover in subjects with abdominal obesity

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Osteoporotic Fractures in Patients With Atrial Fibrillation Treated With Conventional Versus Direct Anticoagulants

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Duration of hyperthyroidism and lack of sufficient treatment are associated with increased cardiovascular risk

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
It remains unknown why proton pump inhibitor (PPI) use may be associated with risk of osteoporotic fractures; evidence of direct effects on calcium absorption or on the osteoclast in humans is weak or absent. However, the ensuing increased gastrin levels may cause histamine production through hypertrophy of gastric enterochromaffin like cells, which could lead to bone loss. We speculated that H1 receptor antagonists (H1RA) used for allergies would then reduce the effect of PPI on bone. We therefore conducted a register-based case-control study comprising 124,655 patients with hospital treated fractures, who were matched 3:1 with non fracture control subjects of the same age and gender. Use of prescription medications was retrieved from the National Prescription Database and data was analyzed using conditional logistic regression analysis. We observed a significant interaction between PPI and H1RA use on fracture risk in general (adjusted OR 0.92, 95% CI 0.87-0.98) though not on hip fracture risk (adjusted OR 0.99, 95% CI 0.85-1.16). There was a significant modification of the interaction by age (p
Original languageEnglish
JournalBone
Volume57
Issue number1
Pages (from-to)269-71
Number of pages3
ISSN8756-3282
DOIs
Publication statusPublished - Nov 2013

ID: 40877441